Ge Healthcare Technologies Inc.

Health Care
Medical Electronics
www.gehealthcare.com

Earnings Score
Moat Score
Safety Score

Market Cap $37.04B
PE 22
Debt $11.32B
Cash $3.57B
EV $44.79B
FCF $1.70B

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	$1.68B
EBIT	$2.51B
ROE	20%
ROA	7%
FCF	$1.70B
Equity	$8.34B
Growth Stability	1
PE	22.11
PEG	-3.35
PB	4.44
P/FCF	21.8
P/S	1.89
Price/Cash	0.1
Debt/Equity	1.36
Debt/FCF	6.66
Net Margins	9%
Gross Margins	41%
Op. Margins	13%
Earnings CAGR	-7%
Sales Growth YoY	1%
Sales Growth QoQ	1%
Sales CAGR	3%
FCF CAGR	-5%
Equity CAGR	-30%
Earnings Stability	-0.82
Earnings Growth YoY	25%
Earnings Growth QoQ	10%
Earnings CAGR 5Y	-7%

Sales CAGR 5Y	3%
FCF CAGR 5Y	-5%
Equity CAGR 5Y	-30%
Earnings CAGR 3Y	3%
Sales CAGR 3Y	3%
FCF CAGR 3Y	-5%
Equity CAGR 3Y	-30%
Market Cap	$37.04B
Revenue	$19.56B
Dividend Yield	0%
Payout Ratio	3%
Assets	$33.86B
Total Debt	$11.32B
Cash	$3.57B
Shares Outstanding	455.91M
EV	44.79B
Earnings Score	6%
Moat Score	89%
Safety Score	79%
Final Score	58%
Working Capital	1.97B
Current Ratio	1.23
Gross Profit	$8.09B
Shares Growth 3y	7%
Equity Growth QoQ	7%
Equity Growth YoY	17%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, Europe, the Middle East, Africa, China, Taiwan, Mongolia, Hong Kong, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging segment offers molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, image-guided therapy, and X-ray systems, as well as women's health products.

SEC Filings

Direct access to Ge Healthcare Technologies Inc. (GEHC) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2022
- 10-K Dec 31

Sector Comparison

How does Ge Healthcare Technologies Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Ge Healthcare Technologies Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

CAGR -7%

Stability -82%

loading chart...

Ge Healthcare Technologies Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Ge Healthcare Technologies Inc..

Years

Calculation mode

= $13B

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	$1.7B	$1.6B	$1.5B	$1.5B	$1.4B	$1.3B	$1.3B	$1.2B	$1.2B	$1.1B	$1.1B	$11B
DCF		$1.5B	$1.3B	$1.1B	$962M	$834M	$724M	$628M	$545M	$472M	$410M	$4.1B
Value	$13B

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2021	12/2022	12/2023	TTM
Net Margins	13%	10%	7%	9%
ROA	-	9%	8%	7%
ROE	-	20%	19%	20%

Net Margins (8.86%)

Net Margins are at a level that is not too high nor too low. They are not a competitive advantage but they are not a competitive disadvantage either.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2021	12/2022	12/2023	TTM
Debt over FCF	-	4.55	6.1	6.66
Debt over Equity	-	0.89	1.46	1.36
Growth Stability	-	-	-	1

Bad Debt/FCF ratio (6.66)

Net Margins are too low to guarantee profitability in case of higher costs or higher interest rates. Furthermore lower margins cause higher earnings’ volatility.

Neutral Debt/Equity ratio (1.36)

The company has a balance between equity and debt that is not too good nor too bad.

Good Graham’s Stability (1)

The company has a good stability in its earnings, which is a sign of a good competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2021	12/2022	12/2023	CAGR 5Y
Revenue YoY growth	-	4%	7%	3%
Earnings YoY growth	-	-15%	-28%	-7%
Equity YoY growth	-	-44%	-24%	-30%
FCF YoY growth	-	34%	-6%	-5%